An update on targeted therapy in metastatic renal cell carcinoma

Giuseppe Lombardi; Fable Zustovich; Martin Donach; Maurizia Dalla Palma; Ornella Nicoletto; Davide Pastorelli

doi:10.1016/j.urolonc.2009.12.018

An update on targeted therapy in metastatic renal cell carcinoma

Giuseppe Lombardi, Fable Zustovich, Martin Donach, Maurizia Dalla Palma, Ornella Nicoletto, Davide Pastorelli

Istituto Oncologico Veneto

Research output: Contribution to journal › Article › peer-review

Abstract

An improved understanding of the biological pathways deregulated in renal cell carcinoma has led to the development of various targeted agents, changing dramatically the therapeutic options for this disease. However, despite numerous opinions and guidelines, the optimal treatment still remains uncertain. In this review, we analyze the most recent published reports regarding the agents sunitinib, bevacizumab, sorafenib, temsirolimus, and everolimus. Moreover, we assess the novel targeted drugs pazopanib and axitinib. In addition, given the likely lack of cross-resistance between these targeting agents, we discuss sequential and combination targeted therapy in metastatic renal cell carcinoma, analyzing the most recent data.

Original language	English
Pages (from-to)	240-246
Number of pages	7
Journal	Urologic Oncology: Seminars and Original Investigations
Volume	30
Issue number	3
DOIs	https://doi.org/10.1016/j.urolonc.2009.12.018
Publication status	Published - May 2012

Keywords

Bevacizumab
Interferon
Renal cancer
Sorafenib
Sunitinib
Targeted therapy

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.1016/j.urolonc.2009.12.018

Fingerprint Dive into the research topics of 'An update on targeted therapy in metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this

@article{1e71fbc32a8045058b486a133c101dbb,

title = "An update on targeted therapy in metastatic renal cell carcinoma",

abstract = "An improved understanding of the biological pathways deregulated in renal cell carcinoma has led to the development of various targeted agents, changing dramatically the therapeutic options for this disease. However, despite numerous opinions and guidelines, the optimal treatment still remains uncertain. In this review, we analyze the most recent published reports regarding the agents sunitinib, bevacizumab, sorafenib, temsirolimus, and everolimus. Moreover, we assess the novel targeted drugs pazopanib and axitinib. In addition, given the likely lack of cross-resistance between these targeting agents, we discuss sequential and combination targeted therapy in metastatic renal cell carcinoma, analyzing the most recent data.",

keywords = "Bevacizumab, Interferon, Renal cancer, Sorafenib, Sunitinib, Targeted therapy",

author = "Giuseppe Lombardi and Fable Zustovich and Martin Donach and {Dalla Palma}, Maurizia and Ornella Nicoletto and Davide Pastorelli",

year = "2012",

month = may,

doi = "10.1016/j.urolonc.2009.12.018",

language = "English",

volume = "30",

pages = "240--246",

journal = "Urologic Oncology",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - An update on targeted therapy in metastatic renal cell carcinoma

AU - Lombardi, Giuseppe

AU - Zustovich, Fable

AU - Donach, Martin

AU - Dalla Palma, Maurizia

AU - Nicoletto, Ornella

AU - Pastorelli, Davide

PY - 2012/5

Y1 - 2012/5

N2 - An improved understanding of the biological pathways deregulated in renal cell carcinoma has led to the development of various targeted agents, changing dramatically the therapeutic options for this disease. However, despite numerous opinions and guidelines, the optimal treatment still remains uncertain. In this review, we analyze the most recent published reports regarding the agents sunitinib, bevacizumab, sorafenib, temsirolimus, and everolimus. Moreover, we assess the novel targeted drugs pazopanib and axitinib. In addition, given the likely lack of cross-resistance between these targeting agents, we discuss sequential and combination targeted therapy in metastatic renal cell carcinoma, analyzing the most recent data.

AB - An improved understanding of the biological pathways deregulated in renal cell carcinoma has led to the development of various targeted agents, changing dramatically the therapeutic options for this disease. However, despite numerous opinions and guidelines, the optimal treatment still remains uncertain. In this review, we analyze the most recent published reports regarding the agents sunitinib, bevacizumab, sorafenib, temsirolimus, and everolimus. Moreover, we assess the novel targeted drugs pazopanib and axitinib. In addition, given the likely lack of cross-resistance between these targeting agents, we discuss sequential and combination targeted therapy in metastatic renal cell carcinoma, analyzing the most recent data.

KW - Bevacizumab

KW - Interferon

KW - Renal cancer

KW - Sorafenib

KW - Sunitinib

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84860278682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860278682&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2009.12.018

DO - 10.1016/j.urolonc.2009.12.018

M3 - Article

C2 - 20456985

AN - SCOPUS:84860278682

VL - 30

SP - 240

EP - 246

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 3

ER -